Company intelligence / Profile preview
iHeart Japan
Kyoto, Kyoto, Japaniheartjapan.jp ↗
- Ownership
- Private
- Development stage
- Other
01
Overview
iHeart Japan is a clinical-stage biotechnology company focused on developing regenerative medicine therapies for cardiovascular diseases. Spun out from Kyoto University, the company utilizes induced pluripotent stem cell (iPSC) technology to create functional cardiomyocyte sheets. These sheets are designed to be transplanted onto the surface of a failing heart to restore cardiac function and promote tissue repair. The company's lead program, IHJ-01, is currently in clinical development for the treatment of severe heart failure, representing a potential paradigm shift in the management of end-stage cardiac conditions.
- Therapeutic areas
- Cardiovascular
- Modalities
- Cell therapyInduced pluripotent stem cell derived therapy
- Industry
- Biotech
02
Drug pipeline
1 asset03
Partnerships
Kyoto University
Beyond the preview
Go deeper on iHeart Japan.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on iHeart Japan.